Review anchor
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
SINGLE PROTEIN · Mus musculus
As of 2026-09-13
Evidence Snapshot
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
CHEMBL2189158
SINGLE PROTEIN
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform as ChEMBL target CHEMBL2189158, mapped to UniProt Q9JHG7. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2189158
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9JHG7
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform matters
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform is reviewed as Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (UniProt Q9JHG7); the current evidence base includes 5 approved drugs, 155 compounds, and 27 assays, with lead potency reaching pChEMBL 9.1.
Protein context
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Sequence length is 1102 aa.
Review this target as Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, mapped to UniProt Q9JHG7. Sequence length is 1102 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9JHG7
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 155 compounds, and 27 assays for this target. The dominant activity type is IC50. CHEMBL4558527 is the current potency anchor at pChEMBL 9.1.
Use CHEMBL4558527 as the tractability anchor when discussing potency (pChEMBL 9.1).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 9.1
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9JHG7, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
155
Total Compounds
27
Total Assays
5
Approved Drugs
IC50: 152.0, EC50: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4558527
|
9.1 | IC50 | Clinical |
|
|
No preferred name
CHEMBL5071394
|
9.1 | IC50 | — |
|
|
No preferred name
CHEMBL5091438
|
9.1 | IC50 | — |
|
|
No preferred name
CHEMBL5090799
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL5076543
|
9.0 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DUVELISIB
CHEMBL3039502
|
2018 |
|
|
CYCLOSPORINE
CHEMBL160
|
1983 |
Source Header